Patents Assigned to PRIMEVAX IMMUNO-ONCOLOGY, INC.
  • Combination immunotherapies for treatment of cancer
    Patent number: 11357795
    Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 14, 2022
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for combination therapy with dengue virus and dendritic cells
    Patent number: 10946080
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: March 16, 2021
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for producing dendritic cells
    Patent number: 10765727
    Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: September 8, 2020
    Assignee: Primevax Immuno-Oncology, Inc.
    Inventors: Bruce W. Lyday, Tony Chen
  • Combination immunotherapies for treatment of cancer
    Patent number: 10675304
    Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: June 9, 2020
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for combination therapy with dengue virus and dendritic cells
    Patent number: 10357553
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: July 23, 2019
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for combination therapy with dengue virus and dendritic cells
    Patent number: 10293038
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: May 21, 2019
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for combination therapy with dengue virus and dendritic cells
    Patent number: 10159727
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: December 25, 2018
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for combination therapy with dengue virus and dendritic cells
    Patent number: 9849167
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 26, 2017
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Compositions and methods for combination therapy with dengue virus and dendritic cells
    Patent number: 9730989
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: August 15, 2017
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday